Data Sheet 4_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…</p>Methods<p>We conducted a 48-month longitudinal, retrospective cohort study of 54 patients with CTP B cirrhosis secondary to MASLD and T2DM who were initiated on SGLT2i (n=27) or insulin (n=27). …”

Data Sheet 7_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…</p>Methods<p>We conducted a 48-month longitudinal, retrospective cohort study of 54 patients with CTP B cirrhosis secondary to MASLD and T2DM who were initiated on SGLT2i (n=27) or insulin (n=27). …”

Data Sheet 11_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

“…</p>Methods<p>We conducted a 48-month longitudinal, retrospective cohort study of 54 patients with CTP B cirrhosis secondary to MASLD and T2DM who were initiated on SGLT2i (n=27) or insulin (n=27). …”

Data Sheet 5_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…</p>Methods<p>We conducted a 48-month longitudinal, retrospective cohort study of 54 patients with CTP B cirrhosis secondary to MASLD and T2DM who were initiated on SGLT2i (n=27) or insulin (n=27). …”

Data Sheet 2_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…</p>Methods<p>We conducted a 48-month longitudinal, retrospective cohort study of 54 patients with CTP B cirrhosis secondary to MASLD and T2DM who were initiated on SGLT2i (n=27) or insulin (n=27). …”

Data Sheet 10_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

“…</p>Methods<p>We conducted a 48-month longitudinal, retrospective cohort study of 54 patients with CTP B cirrhosis secondary to MASLD and T2DM who were initiated on SGLT2i (n=27) or insulin (n=27). …”

Data Sheet 12_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

“…</p>Methods<p>We conducted a 48-month longitudinal, retrospective cohort study of 54 patients with CTP B cirrhosis secondary to MASLD and T2DM who were initiated on SGLT2i (n=27) or insulin (n=27). …”

Data Sheet 6_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…</p>Methods<p>We conducted a 48-month longitudinal, retrospective cohort study of 54 patients with CTP B cirrhosis secondary to MASLD and T2DM who were initiated on SGLT2i (n=27) or insulin (n=27). …”

Data Sheet 1_Association of oxidative balance score with all-cause and cardiovascular mortality among patients with cardio-renal-metabolic disease.docx by Yucui Lin (21598376)

“…Moreover, Higher OBS quartiles were linked to a decreased risk of cardiovascular mortality, while no significant reduction was observed in the lower quartiles [model 3: Q2, Q3, Q4: aHR (95CI%) = 0.96(0.77–1.19), 0.78 (0.63–0.97), 0.70 (0.53–0.93), respectively; P for trend = 0.003]. …”

Data Sheet 1_The association of healthy eating index score and n-3 fatty acid intake with cardiovascular diseases incidence and lipid biomarkers in Alberta’s tomorrow project cohor... by Reihane Taheri (14188808)

“…</p>Discussion<p>Higher overall diet quality but not n-3 FA intake was associated with a lower risk of CVD incidence and non-fasting RC.…”

Table 1_The knowledge paradox: an inverted U-shaped association between HIV knowledge and stigma among older men in Sichuan Province, Southwest China.docx by Zhihua Ye (3133311)

“…Background<p>Older men (≥50 years) in China face elevated HIV infection risks, yet HIV stigma remains a significant barrier to prevention. Although HIV knowledge is frequently assumed to reduce stigma, the evidence is inconsistent. …”

Table 1_Stroke-associated pneumonia with low PaO2/FiO2 ratio in acute large vessel occlusion after endovascular therapy: risk factors and prognosis.docx by Kun Tang (75641)

“…Background<p>Stroke-associated pneumonia (SAP) often occurs after ischemic stroke. A deterioration in SAP manifests itself in a decreased partial pressure oxygen (PaO₂)/fraction of inspired oxygen (FiO₂) ratio, indicating gas exchange dysfunction. …”

PDLB - Balance Sheet by Nguyen Linh (19516642)

“…If we assume PDLB continues to pay 0.5% on this preferred and they have a cost of preferred equity of 10%, then we can calculate the value of this $225M liability as just $11M, with the rest a write-up to equity.…”

Data Sheet 1_Elevated Galectin-3 levels in the tumor microenvironment of ovarian cancer – implication of ROS mediated suppression of NK cell antitumor response via tumor-associated... by Veronika Karlsson (20457788)

“…In co-cultures with NK cells and K562 target cells, we observed that Galectin-3-induced production of reactive oxygen species in neutrophils resulted in decreased NK cell viability and lowered anti-tumor responses.…”

<b>Canagliflozin-induced adaptive metabolism in bone</b> by Sher Bahadur Poudel (20686192)

“…Beyond this, these drugs induce various metabolic changes, including weight loss and impaired bone integrity. There is a significant gap in understanding SGLT2i-induced skeletal changes, as SGLT2 is not expressed in osteoblasts or osteocytes, which use glucose to remodel the bone matrix. …”

Supporting data for “Androgen receptor modulates chemotherapy response in breast cancer” by Chanping You (9067448)

“…TRIM37 overexpression decreased palbociclib sensitivity, while its knockdown enhanced sensitivity and attenuated the effect of AR on RB1 levels and drug response, establishing TRIM37 as a novel E3 ligase that bound RB1 via its MATH and C-terminal domains.…”